Business Wire

CA-CONVIVA

24.8.2022 16:03:10 CEST | Business Wire | Press release

Share
Conviva’s Breakthrough Streaming Analytics Innovation Recognized With Two ACM SIGCOMM Innovation Awards

Conviva , the leading global streaming analytics platform, has been recognized by the Association for Computing Machinery’s Special Interest Group on Data Communications (ACM SIGCOMM) with two prestigious innovation awards: the ACM SIGCOMM Test of Time Award and the SIGCOMM Networking Systems Award. Both awards honor the vision and impact of Conviva’s commitment to data and analytics technology innovation that began with the founding team of Hui Zhang, Aditya Ganjam, Jibin Zhan (Conviva) and Ion Stoica (Conviva, Databricks) defining standards that pushed the industry forward. This team’s work has continued to be foundational to enabling and continuously improving the quality and overall end-user experience that is industry standard in streaming media today. This same core technology has also proven applicable to virtually any industry where technology and business leaders have a business imperative to make the vast amount of their data available to their organizations in real time, and actionable across every aspect of their operations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220824005274/en/

2022 SIGCOMM Test of Time Award

The 2022 ACM SIGCOMM Test of Time Award honors Conviva’s founders for their 2011 paper detailing the direct connection between video quality and user engagement. The annual award recognizes papers published 10 to 12 years in the past that are deemed to offer data, perspective and predictions that still have significance today.

“What we didn’t predict was who would be the winners and losers of the streaming wars,” said Hui Zhang, Conviva Cofounder, Chief Scientist and Chairman of the Board. “What we did know ten years ago, and still holds true today, is that measuring quality and engagement in streaming is core to market growth and who comes out on top. Having this real-time information at their fingertips is mission-critical for publishers and brands to inform any actions to optimize their services and maximize their investment.”

The breakthrough technology that underscored the Test of Time award was documented in a paper, “Understanding the Impact of Video Quality on User Engagement” that was first presented at the 2011 ACM SIGCOMM conference. Its authors were Conviva founders Hui Zhang, Ion Stoica, Aditya Ganjam and Jibin Zhan, along with teammates Florin Dobrian, Asad Awan, Dilip Joseph and Vyas Sekar, an academic collaborator and now Professor of Carnegie Mellon University. The paper pioneered large-scale video measurements and documented an in-depth study conducted on how video quality affects user engagement, which has had a lasting impact on the optimization of streaming media.

The State of Streaming

While video streaming quality has significantly improved in the past 10 years, consumer expectations have also risen to new heights. Nothing short of high resolution and smooth playback all-the-time is acceptable. Detection and identifying root-cause of any barriers to an excellent experience is more challenging than ever due to the complexity of today’s streaming technology ecosystem. Diverse mobile-connected TV devices and associated video/app tech stacks, sophisticated cloud-based media preparation, content distribution, and advertising tech stacks all can contribute to more microscopic and subtle failure modes. More than a trillion-dollar market (ranging from media, entertainment, sports, education and fitness industries) is built on top of streaming, making it table stakes to ensure every media consumer has the best experience.

Each quarter, Conviva conducts an in-depth global review of streaming quality and adoption in a report entitled The State of Streaming.

2022 SIGCOMM Networking Systems Award

A separate SIGCOMM award committee also selected Conviva as the recipient of the 2022 SIGCOMM Networking Systems Award, recognizing the development of a networking system that has had a significant impact on the world of communications and computer networks. According to the committee, Conviva was recognized for “the sustained impact that Conviva has had, from the earliest days of translating published research to a successful real-world system, making a significant impact on real-world streaming systems and CDNs and then continuing to give back to the research community via data sharing and publications.”

“While I am very proud that Conviva has been recognized for its impact on the industry, our contribution to the research community is also very meaningful,” added Zhang. “I am thankful to all of our academic collaborators and talented undergrad and graduate interns from top research programs at CMU, Berkeley, Chicago, Purdue, and USC.”

The 2022 Test of Time winners were selected by an esteemed committee of technology experts that included Fadel Adib (MIT), Venkat Padmanabhan (Microsoft Research India, chair), Jennifer Rexford (Princeton) and Renata Teixeira (Netflix). The 2022 SIGCOMM Networking Systems Award was selected by a committee that included Vishal Misra, Anees Shaikh and Puneet Sharma.

About ACM SIGCOMM

The Association for Computing Machinery (ACM) is the world’s largest educational and scientific computing society, and SIGCOMM is ACM’s professional forum for the discussion of topics in the field of communications and computer networks, including technical design and engineering, regulation and operations, and the social implications of computer networking. The SIG's members are particularly interested in the systems engineering and architectural questions of communication.

About Conviva

Conviva helps streaming businesses act within seconds of observation to grow their business ahead of the competition. Conviva’s leading global streaming analytics platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. Using just a single sensor and a single pipeline, its 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock the incredible opportunity in streaming media. Today the Conviva platform processes nearly 3 trillion streaming data events daily, supporting more than 500 million unique viewers watching 200 billion streams per year across 4 billion applications streaming on devices. To learn more, visit www.conviva.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/convivainc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye